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Aims Clinical presentation of takotsubo syndrome (TTS) mimics acute coronary syndrome (ACS) and does not allow
differentiation. We aimed to develop a clinical score to estimate the probability of TTS and to distinguish TTS from
ACS in the acute stage.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Methods
and results
Patients with TTS were recruited from the International Takotsubo Registry (www.takotsubo-registry.com) and ACS
patients from the leading hospital in Zurich. A multiple logistic regression for the presence of TTS was performed
in a derivation cohort (TTS, n = 218; ACS, n = 436). The best model was selected and formed a score (InterTAK
Diagnostic Score) with seven variables, and each was assigned a score value: female sex 25, emotional trigger 24,
physical trigger 13, absence of ST-segment depression (except in lead aVR) 12, psychiatric disorders 11, neurologic
disorders 9, and QTc prolongation 6 points. The area under the curve (AUC) for the resulting score was 0.971 [95%
confidence interval (CI) 0.96–0.98] and using a cut-off value of 40 score points, sensitivity was 89% and specificity
91%.When patients with a score of≥50 were diagnosed as TTS, nearly 95% of TTS patients were correctly diagnosed.
When patients with a score ≤31 were diagnosed as ACS, ∼95% of ACS patients were diagnosed correctly. The score
was subsequently validated in an independent validation cohort (TTS, n = 173; ACS, n = 226), resulting in a score
AUC of 0.901 (95% CI 0.87–0.93).
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Conclusion The InterTAK Diagnostic Score estimates the probability of the presence of TTS and is able to distinguish TTS from
ACS with a high sensitivity and specificity.
Trial registration: NCT0194762. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Keywords Takotsubo (stress) syndrome • Broken heart syndrome • Acute coronary syndrome • Clinical
score • Disease prevalence
Introduction
Takotsubo syndrome (TTS) is an acute heart failure condition
characterized by acute LV dysfunction with distinct wall motion
abnormalities.1–3 Patients with TTS often present with symptoms
similar to those of acute coronary syndrome (ACS) such as chest
pain and dyspnoea.1,4 In addition, ECG and cardiac biomarkers
including troponin and creatine kinase are commonly changed
in both entities.5–7 As such, clinical presentation on admission
is commonly indistinguishable from classical ACS.8,9 Based on
currently available data, TTS is estimated to occur in 2% of all
patients with ACS.8 However, TTS is still underestimated,10 and
may actually occur at a higher incidence.
Recently, we have demonstrated that in-hospital outcome of
TTS is comparable with that of ACS,1 which indicates that TTS
is not as benign as previously assumed but is in fact a serious and
life-threatening condition. Early cardiac catheterization is neces-
sary to make a correct diagnosis and remains the reference stan-
dard diagnostic test for TTS as for most patients with ACS.11
Non-invasive clinical parameters are urgently needed to identify
those patients, who present with the clinical picture of ACS but
instead suffer from TTS.
The aim of the present study was to develop a sensitive and spe-
cific score to estimate the probability of TTS and to distinguish TTS
from ACS in its initial clinical presentation in the emergency room.
Methods
Study patients and score generation
This substudy included patients from the recently pub-
lished International Takotsubo Registry (InterTAK Registry; .
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.. www.takotsubo-registry.com).1,12 Patients with TTS were included
in the present study if they met modified Mayo Clinic diagnostic
criteria:1,8 (i) systolic and diastolic LV wall motion impairment; (ii)
absence of angiographic evidence of plaque rupture; absence of
obstructive coronary artery disease (CAD) which is responsible for
the respective wall motion abnormality; (iii) ECG abnormalities
or increased troponin values; and (iv) absence of myocardi-
tis/pheochromocytoma. Exceptions to the criteria include: (i)
concomitant CAD was not an exclusion criterion; (ii) patients
with focal TTS matching all other criteria, in whom the wall motion
abnormality was congruent with a single coronary artery territory,
were not excluded; and (iii) patients who died in the acute setting
before confirmation of wall motion recovery were not excluded.
When eligibility for inclusion was unclear, cases were studied by all
members of the TTS team investigators in order to reach consensus.
To generate the InterTAK Diagnostic Score, a univariate analysis
was performed in a derivation cohort (218 TTS patients vs. 436 ACS
patients from the Zurich ACS Registry, 1:2 random assignment). From
those parameters, which were significantly different between TTS and
ACS and can be easily obtained in the emergency room without any
imaging modality or laboratory values, seven were selected to build the
score, as described in the statistical analysis section. Thereafter, the
score was validated in an independent validation cohort (TTS, n=173;
ACS, n= 226) consisting of prospectively enrolled TTS patients from
the InterTAK Registry and ACS patients from the Zurich ACS Registry.
Statistical analysis
For comparison of patients’ characteristics between TTS and ACS in
the derivation cohort Pearson 𝜒2 test for nominal data, paired Stu-
dent’s t-test, or Mann–Whitney U-test for continuous data were used.
In order to develop a score for predicting the diagnosis of TTS, a logistic
regression with the following potential predictors was performed in the
© 2016 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 1 Characteristics of patients from the derivation cohorta
Baseline characteristics Takotsubo syndrome
(n= 218)
Acute coronary syndrome
(n= 436)
P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Demographics
Female sex, n (%) 206/218 (94.5) 103/436 (23.6) <0.001
Age, years, mean± SD 67.3±13.2 (n= 218) 63.4±12.1 (n= 436) <0.001
Triggering factors, n (%)
Physical 109/218 (50.0) 89/436 (20.4) <0.001
Emotional 93/218 (42.7) 11/436 (2.5) <0.001
Both emotional and physical trigger 19/218 (8.7) 0/436 (0.0) <0.001
No evident trigger 37/218 (17.0) 336/436 (77.1) <0.001
Takotsubo syndrome type, n (%)
Apical type 168/218 (77.1)
Midventricular type 43/218 (19.7)
Basal type 5/218 (2.3)
Focal type 2/218 (0.9)
Acute coronary syndrome type, n (%)
STEMI 235/436 (53.9)
NSTEMI 163/436 (37.4)
Unstable angina pectoris 38/436 (8.7)
Symptoms on admission, n (%)
Chest pain 148/218 (67.9) 385/436 (88.3) <0.001
Dyspnoea 113/218 (51.8) 110/436 (25.2) <0.001
Cardiac biomarkers on admission, median (IQR)
Troponin, factor increase in ULNb 6.67 (2.50–19.00) n=199 3.75 (0.68–15.84) n= 378 0.003
Creatine kinase, factor increase in ULN 0.81 (0.48–1.42) n=139 1.17 (0.61–3.16) n= 397 <0.001
BNP, factor increase in ULNc 5.14 (1.67–13.17) n=107 1.69 (0.54–6.44) n= 253 <0.001
Inflammatory markers on admission, median (IQR)
CRP, mg/L 5.40 (1.85–15.50) n= 125 3.65 (1.20–9.73) n= 362 0.06
WBC, 103/μL 10.05 (7.51–13.21) n= 201 10.16 (8.17–12.93) n= 397 0.39
ECG on admission, n (%)
Sinus rhythm 206/218 (94.5) 417/436 (95.6) 0.52
Atrial fibrillation 12/218 (5.5) 19/436 (4.4) 0.52
ST-segment elevation 94/218 (43.1) 202/436 (46.3) 0.44
ST-segment depression 23/218 (10.6) 126/436 (28.9) <0.001
T-wave inversion 77/218 (35.3) 102/436 (23.4) 0.001
Left bundle branch block 11/218 (5.0) 16/436 (3.7) 0.40
QTc prolongation 83/218 (38.1) 111/436 (25.5) 0.001
Vital signs, mean± SD
Heart rate, b.p.m. 87.6± 23.0 (n= 205) 73.3±14.8 (n= 336) <0.001
Systolic blood pressure, mmHg 128.6± 31.8 (n= 209) 128.8± 25.6 (n= 401) 0.92
Diastolic blood pressure, mmHg 74.1±18.4 (n= 209) 71.7±13.7 (n= 401) 0.10
Cardiovascular risk factors, n (%)
Hypertension 142/218 (65.1) 243/436 (55.7) 0.021
Diabetes mellitus 27/218 (12.4) 69/436 (15.8) 0.24
Current smoking 77/218 (35.3) 239/436 (54.8) <0.001
Hypercholesterolaemia 76/218 (34.9) 161/436 (36.9) 0.61
Positive family history 68/218 (31.2) 99/436 (22.7) 0.019
Comorbidities, n (%)
Cancer 39/218 (17.9) 48/436 (11.0) 0.015
COPD or asthma 32/218 (14.7) 23/436 (5.3) <0.001
Neurologic disordersd 76/218 (34.9) 31/436 (7.1) <0.001
Psychiatric disordersd 115/218 (52.8) 42/436 (9.6) <0.001
Affective disordersd 63/218 (28.9) 24/436 (5.5) <0.001
BNP, brain natriuretic peptide; COPD, chronic obstructive pulmonary disease; CRP, C-reactive protein; ECG, electrocardiogram; IQR, interquartile range; NSTEMI,
non-ST-segment elevation myocardial infarction; QTc, QT interval corrected for heart rate; SD, standard deviation; STEMI, ST-segment elevation myocardial infarction;
ULN upper limit of normal; WBC, white blood cell count.
aDepicted are the cohorts of patients with takotsubo syndrome and acute coronary syndrome: 1:2 random assignment.
bIncluding upper limits of the normal range for troponin T, high-sensitivity troponin T, and troponin I.
cIncluding upper limits of the normal range for BNP and NT-proBNP.
dIncluding patients with either acute/former/chronic disorders.
© 2016 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 1 Clinical predictors for the diagnosis of takotsubo syndrome (TTS). Multiple logistic regression analysis. Odds ratios (OR) of the
parameters female sex, emotional trigger, physical trigger, absence of ST-segment depression, psychiatric disorders, neurologic disorders, and
QTc prolongation, which were chosen to build the InterTAK Diagnostic Score. Error bars demonstrate the 95% confidence interval (CI).
*Except in lead aVR.
derivation cohort: female sex, age, physical trigger, emotional trigger,
ST-segment elevation, ST-segment depression, T-wave inversion, left
bundle branch block, QTc prolongation, cancer, COPD/asthma, neu-
rologic disorders, psychiatric disorders, and affective disorders. The
bestglm package13 in R (version 2.15.1) was used for model selection
with the Bayesian information criterion. We then developed a score by
scaling and rounding the regression coefficients of the resulting multiple
regression model.
A receiver operating characteristic (ROC) curve analysis, that
reported the area under the curve (AUC) with a 95% confidence
interval (CI), was performed to illustrate the predictive performance
of the score.
A univariate logistic regression with the score as predictor was per-
formed to develop a formula for the probability of TTS conditional on
the score. The conditional odds in the derivation cohort is odds= exp
(intercept+ coefficient× score) and the corresponding probability is
odds/(1+ odds).
The predictive performance of the score in the validation cohort
was assessed using the AUC, and the calibration was assessed by
comparing the observed proportion with the predicted probability.
As the predicted probability depends on the prevalence, the con-
ditional odds were adjusted accordingly: conditional odds in new
cohort= conditional odds in derivation cohort× overall odds in new
cohort/overall odds in derivation cohort.
A two-sided P-value ≤0.05 was considered statistically significant.
Statistical analyses were performed using IBM SPSS Statistics, version
21.0 (IBM Corp., Armonk, NY, USA). Graphs were compiled with
Prism 6 (GraphPad, La Jolla, CA, USA).
Results
Study groups
Patients with TTS were mainly females (94.5%) and signif-
icantly older than patients with ACS (67.3± 13.2 years vs.
63.4± 12.1 years, P< 0.001). Physical and emotional triggers
were more prevalent among the TTS population (P< 0.001, for
both comparisons). The leading symptom on admission was chest
pain, however less frequently observed in the TTS group (67.9%
vs. 88.3%, P< 0.001), while dyspnoea was more prevalent among
TTS patients (51.8% vs. 25.2%, P< 0.001). The upper limits of ..
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.. normal for troponin and brain natriuretic peptide showed higher
admission values in TTS, while creatine kinase was higher in
patients with ACS. Inflammatory markers were increased in both
entities but not significantly different by comparison. ST-segment
depression occurred less frequently in the TTS group (10.6% vs.
28.9%, P< 0.001) while T-wave inversion was more often noted
(35.3% vs. 23.4%, P= 0.001). Systolic blood pressure on admission
was not substantially different between groups, but higher heart
rates were found in TTS (87.6± 23.0 b.p.m. vs. 73.3±14.8 b.p.m.,
P< 0.001). Notably, the prevalence of the comorbidities cancer,
COPD/asthma, and psychiatric and neurologic disorders was
substantially higher in the TTS group.
Baseline characteristics of patients with TTS and ACS are shown
in Table 1.
Takotsubo syndrome score derivation
and validation
The score derivation process resulted in seven parameters ranked
by relevance using their respective odds ratios (OR). Points were
assigned to each criterion, depending on their diagnostic impor-
tance: female sex 25 points, emotional trigger 24 points, physical
trigger 13 points, absence of ST-segment depression (except in
lead aVR) 12 points, psychiatric disorders 11 points, neurologic
disorders 9 points, and QTc prolongation 6 points. Points were
then added in a given patient to result in a score value ranging from
0 (no criterion fulfilled) up to 100 (all criteria fulfilled; Figure 1).
Using a cut-off value of 40 score points, sensitivity was 89%
and specificity was 91% for the presence of TTS. When patients
with a score value of ≥50 were diagnosed as TTS, nearly 95% of
TTS patients were diagnosed correctly (sensitivity 94.7%). When
patients with a score value ≤31 were diagnosed as ACS, ∼95% of
ACS patients were diagnosed correctly. The logistic regression with
the InterTAK Diagnostic Score as predictor yielded an intercept
of −7.63 and a regression coefficient of 0.171 (SE 0.015). The cor-
responding OR was 1.19 (95% CI 1.15–1.22) per point. Figure 2A
shows the predicted probabilities of TTS for the patients in the
derivation cohort. The AUC of the InterTAK Diagnostic Score in
© 2016 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 2 InterTAK Diagnostic Score for predicting the presence of takotsubo syndrome (TTS). (A) Relationship of risk score values (x-axis)
and predicted probability of TTS (y-axis), as computed by logistic regression. Every given score value matches a predicted probability of TTS
resulting in a sigmoid curve. Left: values from the acute coronary syndrome (ACS) derivation cohort (red circles). Right: values from the
TTS derivation cohort (blue circles). Median and interquartile ranges in each group were drawn into the corresponding graph. When patients
with a score value of ≥50 are diagnosed as TTS, nearly 95% of TTS patients are found (sensitivity 94.7%). When patients with a score value
between 0 and 31 are diagnosed as ACS, almost 95% of ACS patients are diagnosed correctly (specificity 93.6%). (B and C) Receiver operating
characteristic curves demonstrating an area under the curve (AUC) of 0.971 [95% confidence interval (CI) 0.96–0.98 in the derivation cohort
(B, left)] and an AUC of 0.901 (95% CI 0.87–0.93) in the validation cohort (C, left)]. The graphs on the right-hand side in (B) and (C) show the
percentages of TTS (blue) and ACS (red) per 10 score value points. Squares indicate the predicted probability of each corresponding bar.
© 2016 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 3 Predicted probability of takotsubo syndrome (TTS) corresponding to the prevalence in clinical practice. Horizontal lines indicate
the prevalence of TTS in the validation cohort (orange), derivation cohort (green), and in clinical practice at the University Hospital Zurich
from 2011 to 2015 (blue). Sigmoid curves show the predicted probabilities for a given score value in the derivation cohort (green), validation
cohort (orange), and in clinical practice (blue).
the derivation cohort was 0.971 (95% CI 0.96–0.98) (Figure 2B).
The right-hand panel in Figure 2B shows the observed and the pre-
dicted proportions of TTS patients depending on the score value.
Prospective validation of the InterTAK Diagnostic Score in an inde-
pendent cohort (173 TTS patients and 226 ACS patients) revealed
an AUC of 0.901 (95% CI 0.87–0.93) (Figure 2C). The overall cal-
ibration was excellent; the mean predicted probability of TTS was
42% compared with the prevalence of 43%. The right-hand panel
in Figure 2C shows the observed and the predicted proportions of
TTS patients in the validation cohort depending on the score value.
Correction for disease prevalence
The predicted probability of TTS depends on the prevalence of the
disease in clinical practice. Based on data from the leading hospital
in Zurich from 2011 to 2015, we assume a prevalence of 4.1%
(Figure 3). For each increase by 10 points, the odds increased by a
factor of >5 (OR^10= 5.5). Thus, a patient with 30 score points
has a predicted probability of <1%, a patient with 50 points has
a probability of 18%, and one with 60 points has a probability of
>50% of suffering from TTS (Figure 3).
The InterTAK Diagnostic Score calculator is accessible under
www.takotsubo-registry.com.
Discussion
Takotsubo syndrome is an acute heart failure syndrome and is the
most important differential diagnosis of ACS due to its similar
presentation in clinical symptoms, ECG, and cardiac biomarker
changes. To date, no non-invasive tools are available to distinguish
between both entities in the acute phase. Therefore, early cardiac
catheterization is necessary to differentiate TTS from ACS. .
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. Scoring systems are widely used in clinical medicine to help guide
clinical decision-making, such as the Wells score, TIMI risk score,
or the CHA2DS2-VASc score, among many others.
14–16 However,
to date, such scoring systems are not available to distinguish TTS
from ACS based on clinical parameters in the acute setting.
Therefore, in order to facilitate the initial evaluation in the
emergency room prior to cardiac imaging, we developed a clinical
score which estimates the probability of the presence of TTS
and differentiates it from ACS. The InterTAK Diagnostic Score
comprises seven clinical parameters, which can be easily obtained
in the emergency department. Of note, all those parameters
have previously been associated with TTS: the disease shows
a strong preponderance toward female sex, with ∼90% of all
patients being women.1 Emotional and physical trigger factors
are a typical feature of TTS,17 although their occurrence is not
mandatory.1,4 ST-segment depression is a common finding in ACS,
but uncommon in TTS.1,18–20 In contrast, QTc prolongation is an
ECG hallmark of TTS patients.1,18,20 The prevalence of neurologic
or psychiatric disorders is twice as high in TTS compared with
ACS.1 Therefore, neurologic and psychiatric disorders may play a
significant role in the development of TTS or serve as risk factors.
As all these parameters can be easily obtained and were each
strongly different between TTS and ACS, we reasoed that the
combination of all seven parameters would result in a powerful
predictive score for the diagnosis of TTS. While the InterTAK
Diagnostic Score can be easily calculated on admission and would
thus be helpful for initial evaluation, it provides a probability and is
not diagnostic per se. As such, a low score does not absolutely rule
out TTS, nor does a high score definitely confirm the diagnosis.
Nonetheless, the InterTAK Diagnostic Score provides a probability
of TTS on admission. This is of importance since TTS mimics ACS
in terms of symptoms, biomarkers, and ECG findings. This score
may also be valuable in clinical practice to weigh the risk and
© 2016 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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benefit of coronary angiography, especially in old fragile patients. In
addition, it may help to avoid unnecessary coronary intervention
and associated platelet inhibition, for example in patients with a
moderate proximal LAD stenosis and apical ballooning when risk
of bleeding is present and dual antiplatlet therapy has to be avoided.
Of note, the composition of the study cohorts used for score
derivation does not reflect the true prevalence of TTS. In our study,
the ratio of TTS vs. ACS was 1:2 for derivation (218 patients vs. 436
patients) and 1:1.3 for validation (173 patients vs. 226 patients).
However, the real life ratio for TTS vs. ACS is between 1:50 and
1:25, which means that 2–4% of patients with ACS symptoms in
fact suffer from TTS and not 30% or 50% such as in our cohorts.
Mathematically, correction for this bias revealed that a given score
value relates to a somewhat lower probability of TTS under real-life
conditions, but with a still very strong association of high values
with the diagnosis of TTS.
Conclusion
The InterTAK Diagnostic Score estimates the presence of TTS
with high sensitivity and distinguishes TTS from ACS with high
specificity. The score can be quickly calculated in the emergency
room just with clinical parameters. Prospective studies under
clinical routine conditions are now needed to assess the diagnostic
validity of this novel non-invasive test.
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